Norges Bank Evolus, Inc. Transaction History

Norges Bank

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$7.6 - $10.53 $468,920 - $649,701	61,700 New	61,700 $649,000
Q3 2023 Nov 13, 2024	BUY	$7.15 - $10.2 $923,065 - $1.32 Million	129,100 New	129,100 $1.18 Million
Q2 2023 Aug 14, 2024	BUY	$7.23 - $10.52 $1.19 Million - $1.73 Million	164,800 New	164,800 $1.2 Million
Q1 2023 May 15, 2024	BUY	$7.81 - $11.05 $1.29 Million - $1.82 Million	164,800 New	164,800 $1.39 Million
Q1 2022 May 09, 2022	SELL	$5.22 - $11.78 $275,094 - $620,806	-52,700 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$5.37 - $8.38 $282,999 - $441,626	52,700 New	52,700 $343,000
Q3 2021 Nov 14, 2022	BUY	$7.36 - $13.67 $426,144 - $791,493	57,900 New	57,900 $441,000
Q3 2021 Nov 05, 2021	SELL	$7.36 - $13.67 $579,232 - $1.08 Million	-78,700 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$8.42 - $13.96 $662,654 - $1.1 Million	78,700 New	78,700 $996,000

168

47.8M

130K

51K

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $608M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.